Tests inotuzumab ozogamicin added to chemo-immunotherapy in high-risk childhood B-cell leukemia
Tests inotuzumab ozogamicin with chemo-immunotherapy in people with high-risk B-cell acute lymphoblastic leukemia.
Key facts
- Who runs it
- Children's Oncology Group
- Where
- Akron, Albany, Albuquerque, Allentown, Amarillo, Anchorage, Ann Arbor, Asheville, Atlanta, Augusta, Aurora, Austin, Baltimore, Bangor, Bethesda, Birmingham, Boise, Boston, Brooklyn, Buffalo, Burlington, Chapel Hill, Charleston, Charlotte, Charlottesville, Chattanooga, Chicago, Cincinnati, Cleveland, Columbia, Columbus, Corpus Christi, Dallas, Danville, Dayton, Denver, Des Moines, Detroit, Downey, Duarte, Durham, East Lansing, El Paso, Falls Church, Fargo, Fort Lauderdale, Fort Myers, Fort Worth, Gainesville, Grand Rapids, Green Bay, Greenville, Hackensack, Hartford, Hershey, Hollywood, Honolulu, Houston, Huntington, Indianapolis, Iowa City, Jackson, Jacksonville, Kalamazoo, Kansas City, Knoxville, Las Vegas, Lebanon, Lexington, Little Rock, Loma Linda, Long Beach, Los Angeles, Louisville, Loxahatchee Groves, Lubbock, Macon, Madera, Madison, Marshfield, Maywood, McAllen, Mesa, Miami, Milwaukee, Mineola, Minneapolis, Mobile, Morgantown, Morristown, Nashville, Neptune City, New Brunswick, New Haven, New Hyde Park, New Orleans, New York, Newark, Norfolk, Oak Lawn, Oakland, Oklahoma City, Omaha, Orange, Orlando, Palo Alto, Park Ridge, Paterson, Pensacola, Peoria, Philadelphia, Phoenix, Pittsburgh, Portland, Portsmouth, Providence, Reno, Richmond, Roanoke, Rochester, Royal Oak, Sacramento, Salt Lake City, San Antonio, San Diego, San Francisco, Santa Barbara, Savannah, Scarborough, Seattle, Sioux Falls, Spokane, Springfield, St Louis, St. Petersburg, Stony Brook, Syracuse, Tacoma, Tampa, Temple, The Bronx, Toledo, Torrance, Tucson, Tulsa, Valhalla, Washington D.C., West Palm Beach, Wichita, Wilmington, Winfield, Winston-Salem, and Worcester, United StatesSee the 203 sitesAlso in 4 other countries, 28 sites
- Trial code
- Registry title
- Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 5,951 people, planned
- Started
- 31 Oct 2019
- Expected to end
- 31 Mar 2032
- Type of study
- Interventional, 4 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Biospecimen Collection
- Blinatumomab
- Bone Marrow Aspiration
- Bone Marrow Biopsy
- Bone Scan
- Calaspargase Pegol
- Computed Tomography
- Cyclophosphamide
- Cytarabine
- Daunorubicin Hydrochloride
- Dexamethasone
- Doxorubicin Hydrochloride
- Inotuzumab Ozogamicin
- Leucovorin Calcium
- Magnetic Resonance Imaging
- Mercaptopurine
- Methotrexate
- Pegaspargase
- Positron Emission Tomography
- Prednisolone
- Prednisone
- Questionnaire Administration
- Radiation Therapy
- Thioguanine
- Vincristine Sulfate
- Record updated
- 25 August 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children and young people with newly diagnosed B-cell acute lymphoblastic leukemia (B-ALL), mixed phenotype acute leukemia (MPAL) or B-lymphoblastic lymphoma (B-LLy). It tests adding inotuzumab ozogamicin to chemotherapy.
- Age
- Older than 365 days and younger than 25 years.
- Sex
- All sexes can join.
- Disease stage
- Newly diagnosed B-ALL or MPAL with at least 25% blasts in the bone marrow, or newly diagnosed B-LLy Murphy stage III or IV. B-LLy stage I or II can join only with steroid pretreatment. B-ALL at age 1-9.99 years needs a white blood cell count of 50,000/uL or more, or testicular leukemia, CNS leukemia (CNS3) or steroid pretreatment. B-ALL at age 10-24.99 years can have any white blood cell count.
- Earlier treatment
- No earlier cytotoxic chemotherapy for this or any earlier cancer. Steroid pretreatment, steroid cytoreduction and intrathecal cytarabine are allowed. No more than 72 hours of hydroxyurea in the week before treatment starts.
- Biomarker or test result
- Not required. Central confirmation of the MPAL diagnosis must happen within 22 days of enrollment.
Main reasons for not taking part
- Down syndrome
- Acute undifferentiated leukemia, T-lymphoblastic lymphoma or lymphoma that cannot be classified
- Known Charcot-Marie-Tooth disease
- Known MYC translocation linked to mature (Burkitt) B-cell ALL
- Pregnancy, or breastfeeding during the study and for 2 months after the last inotuzumab ozogamicin dose
The registry criteria, word for word
Show all 27 criteriaShow less
Who can take part
- B-ALL and MPAL patients must be enrolled on APEC14B1 and consented to eligibility studies (Part A) prior to treatment and enrollment on AALL1732. Note that central confirmation of MPAL diagnosis must occur within 22 days of enrollment for suspected MPAL patients. If not performed within this time frame, patients will be taken off protocol
- APEC14B1 is not a requirement for B-LLy patients but for institutional compliance every patient should be offered participation in APEC14B1. B-LLy patients may directly enroll on AALL1732
- Patients must be > 365 days and < 25 years of age
- Initial white blood cell count (WBC) criteria for patients with B-ALL (within 7 days prior to the start of protocol-directed systemic therapy):; Age 1-9.99 years: WBC >= 50,000/uL; Age 10-24.99 years: Any WBC; Age 1-9.99 years: WBC < 50,000/uL with one or more of the following:; Testicular leukemia; CNS leukemia (CNS3); Steroid pretreatment
- Initial white blood cell count (WBC) criteria for patients with MPAL (within 7 days prior to the start of protocol-directed systemic therapy):; Age 1-24.99 years: any WBC NOTE: Patients enrolled as suspected MPAL but found on central confirmatory testing to have B-ALL must meet the B-ALL criteria above (age, WBC, extramedullary disease, steroid pretreatment) to switch to the B-ALL stratum before the end of induction
- Patient has newly diagnosed B-ALL or MPAL (by World Health Organization [WHO] 2016 criteria) with >= 25% blasts on a bone marrow (BM) aspirate; OR If a BM aspirate is not obtained or is not diagnostic of acute leukemia, the diagnosis can be established by a pathologic diagnosis of acute leukemia on a BM biopsy; OR A complete blood count (CBC) documenting the presence of at least 1,000/uL circulating leukemic cells if a bone marrow aspirate or biopsy cannot be performed
- Patient has newly diagnosed B-LLy Murphy stages III or IV
- Patient has newly diagnosed B-LLy Murphy stages I or II with steroid pretreatment
- Note: For B-LLy patients with tissue available for flow cytometry, the criterion for diagnosis should be analogous to B-ALL. For tissue processed by other means (i.e., paraffin blocks), the methodology and criteria for immunophenotypic analysis to establish the diagnosis of B-LLy defined by the submitting institution will be accepted
- Central nervous system (CNS) status must be determined prior to enrollment based on a sample obtained prior to administration of any systemic or intrathecal chemotherapy, except for steroid pretreatment and cytoreduction. Note that once cerebrospinal fluid (CSF) has been collected, protocol therapy can be initiated while final determination of CNS status is pending. It is recommended that intrathecal cytarabine be administered at the time of the diagnostic lumbar puncture. This is usually done at the time of the diagnostic bone marrow or venous line placement to avoid a second lumbar puncture. This is allowed prior to enrollment. Systemic chemotherapy must begin within 72 hours of this intrathecal therapy
- Direct bilirubin < 2.0 mg/dL (34 micromoles/L)
- Alanine aminotransferase (ALT) ≤ 10x upper limit of normal (ULN). For the purposes of this study, the ULN for ALT is defined as 45 U/L
- Exceptions to this include patients with known Gilbert's Syndrome, or those with hepatic involvement from leukemic or lymphomatous infiltration
- All patients and/or their parents or legal guardians must sign a written informed consent
- All institutional, Food and Drug Administration (FDA), and NCI requirements for human studies must be met
Who cannot take part
- With the exception of steroid pretreatment and steroid cytoreduction or the administration of intrathecal cytarabine, patients must not have received any prior cytotoxic chemotherapy for the current diagnosis of B-ALL, MPAL, or B-LLy or for any cancer diagnosed prior to initiation of protocol therapy on AALL1732
- Patients who have received > 72 hours of hydroxyurea within one week prior to start of systemic protocol therapy
- For Murphy stage III/IV B-LLy patients, or stage I/II patients with steroid pretreatment, the following additional exclusion criteria apply:; T-lymphoblastic lymphoma; Morphologically unclassifiable lymphoma; Absence of both B-cell and T-cell phenotype markers in a case submitted as lymphoblastic lymphoma
- Patients requiring radiation at diagnosis
- Female patients who are pregnant, since fetal toxicities and teratogenic effects have been noted for several of the study drugs. A pregnancy test is required for female patients of childbearing potential
- Patients with Down syndrome are not eligible
- Patients with known Charcot-Marie-Tooth disease
- Patients with B-ALL or MPAL who do not have sufficient diagnostic bone marrow submitted for APEC14B1 testing and who do not have a peripheral blood sample submitted containing > 1,000/uL circulating leukemia cells
- Patients with acute undifferentiated leukemia (AUL) are not eligible
- Patients with known MYC translocation associated with mature (Burkitt) B-cell ALL, regardless of blast immunophenotype
- Lactating women who plan to breastfeed their infants while on study and for 2 months after the last dose of inotuzumab ozogamicin
- Sexually active patients of reproductive potential who have not agreed to use an effective contraceptive method for the duration of study participation. For those patients randomized to inotuzumab ozogamicin, there is a minimum of 8 months after the last dose of inotuzumab ozogamicin for females and 5 months after the last dose of inotuzumab ozogamicin for males
Where in United States
Also in 4 other countries, 28 sites
- Children's Hospital Medical Center of AkronAkron, United StatesContact: Erin Wright (principal investigator)Taking people
- Albany Medical CenterAlbany, United StatesContact: Lauren R. Weintraub (principal investigator)Taking people
- Presbyterian HospitalAlbuquerque, United StatesContact: Beeling Armijo (principal investigator)Taking people
- University of New Mexico Cancer CenterAlbuquerque, United StatesContact: Jessica M. Valdez (principal investigator)Taking people
- Lehigh Valley Hospital-Cedar CrestAllentown, United StatesContact: Jacob A. Troutman (principal investigator)Taking people
- Texas Tech University Health Sciences Center-AmarilloAmarillo, United StatesNo longer taking part
- Providence Alaska Medical CenterAnchorage, United StatesContact: Brenda J. Wittman (principal investigator)Taking people
- C S Mott Children's HospitalAnn Arbor, United StatesContact: Joshua W. Goldman (principal investigator)Taking people
- Mission HospitalAsheville, United StatesContact: Douglas J. Scothorn (principal investigator)Taking people
- Children's Healthcare of Atlanta - Arthur M Blank HospitalAtlanta, United StatesContact: Ryan J. Summers (principal investigator)Taking people
- Augusta University Medical CenterAugusta, United StatesContact: Colleen H. McDonough (principal investigator)Taking people
- Children's Hospital ColoradoAurora, United StatesContact: Kelly W. Maloney (principal investigator)Taking people
- Dell Children's Medical Center of Central TexasAustin, United StatesContact: Shannon M. Cohn (principal investigator)Taking people
- Johns Hopkins University/Sidney Kimmel Cancer CenterBaltimore, United StatesContact: Stacy L. Cooper (principal investigator)Taking people
- Sinai Hospital of BaltimoreBaltimore, United StatesContact: Jason M. Fixler (principal investigator)Taking people
- University of Maryland/Greenebaum Cancer CenterBaltimore, United StatesContact: Teresa A. York (principal investigator)Taking people
- Eastern Maine Medical CenterBangor, United StatesTaking people
- Walter Reed National Military Medical CenterBethesda, United StatesContact: Kip R. Hartman (principal investigator)Taking people
- Children's Hospital of AlabamaBirmingham, United StatesContact: Matthew A. Kutny (principal investigator)Taking people
- Saint Luke's Cancer Institute - BoiseBoise, United StatesContact: Martha M. Pacheco (principal investigator)Taking people
- Dana-Farber Cancer InstituteBoston, United StatesContact: Melissa A. Burns (principal investigator)Taking people
- Massachusetts General Hospital Cancer CenterBoston, United StatesContact: Alison M. Friedmann (principal investigator)Taking people
- Tufts Children's HospitalBoston, United StatesNo longer taking part
- Maimonides Medical CenterBrooklyn, United StatesContact: Mahmut Y. Celiker (principal investigator)Taking people
- Roswell Park Cancer InstituteBuffalo, United StatesContact: Clare J. Twist (principal investigator)Taking people
- University of Vermont and State Agricultural CollegeBurlington, United StatesContact: Jessica L. Heath (principal investigator)Taking people
- UNC Lineberger Comprehensive Cancer CenterChapel Hill, United StatesContact: Thomas B. Alexander (principal investigator)Taking people
- Medical University of South CarolinaCharleston, United StatesContact: Jacqueline M. Kraveka (principal investigator)Taking people
- West Virginia University Charleston DivisionCharleston, United StatesContact: Mohamad H. Badawi (principal investigator)Taking people
- Carolinas Medical Center/Levine Cancer InstituteCharlotte, United StatesContact: Joel A. Kaplan (principal investigator)Taking people
- Novant Health Presbyterian Medical CenterCharlotte, United StatesContact: Holly Edington (principal investigator)Taking people
- University of Virginia Cancer CenterCharlottesville, United StatesContact: Brian C. Belyea (principal investigator)Taking people
- T C Thompson Children's HospitalChattanooga, United StatesContact: Benjamin A. Mixon (principal investigator)Taking people
- Lurie Children's Hospital-ChicagoChicago, United StatesContact: Sara Zarnegar-Lumley (principal investigator)Taking people
- University of Chicago Comprehensive Cancer CenterChicago, United StatesContact: Gabrielle Lapping-Carr (principal investigator)Taking people
- University of IllinoisChicago, United StatesContact: Dipti S. Dighe (principal investigator)Taking people
- Cincinnati Children's Hospital Medical CenterCincinnati, United StatesContact: Erin H. Breese (principal investigator)Taking people
- Cleveland Clinic FoundationCleveland, United StatesContact: Matteo M. Trucco (principal investigator)Taking people
- Rainbow Babies and Childrens HospitalCleveland, United StatesContact: Duncan S. Stearns (principal investigator)Taking people
- Prisma Health Richland HospitalColumbia, United StatesContact: Stuart L. Cramer (principal investigator)Taking people
- University of Missouri Children's HospitalColumbia, United StatesContact: Barbara A. Gruner (principal investigator)Taking people
- Nationwide Children's HospitalColumbus, United StatesContact: Mark A. Ranalli (principal investigator)Taking people
- Driscoll Children's HospitalCorpus Christi, United StatesContact: Nkechi I. Mba (principal investigator)Taking people
- Medical City Dallas HospitalDallas, United StatesContact: Maurizio L. Ghisoli (principal investigator)Taking people
- UT Southwestern/Simmons Cancer Center-DallasDallas, United StatesContact: Tamra L. Slone (principal investigator)Taking people
- Geisinger Medical CenterDanville, United StatesContact: Jagadeesh Ramdas (principal investigator)Taking people
- Dayton Children's HospitalDayton, United StatesContact: Jordan M. Wright (principal investigator)Taking people
- Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical CenterDenver, United StatesContact: Florence Choo (principal investigator)Taking people
- Blank Children's HospitalDes Moines, United StatesContact: Samantha L. Mallory (principal investigator)Taking people
- Children's Hospital of MichiganDetroit, United StatesContact: Alissa M. Martin (principal investigator)Taking people
- Henry Ford Health Saint John HospitalDetroit, United StatesNo longer taking part
- Kaiser Permanente Downey Medical CenterDowney, United StatesContact: Robert M. Cooper (principal investigator)Taking people
- City of Hope Comprehensive Cancer CenterDuarte, United StatesContact: Anna B. Pawlowska (principal investigator)Taking people
- Duke University Medical CenterDurham, United StatesContact: Jessica M. Sun (principal investigator)Taking people
- Michigan State UniversityEast Lansing, United StatesNo longer taking part
- El Paso Children's HospitalEl Paso, United StatesContact: Benjamin Carcamo (principal investigator)Taking people
- Inova Fairfax HospitalFalls Church, United StatesContact: Robin Y. Dulman (principal investigator)Taking people
- Sanford Broadway Medical CenterFargo, United StatesContact: Samuel J. Milanovich (principal investigator)Taking people
- Broward Health Medical CenterFort Lauderdale, United StatesContact: Hector M. Rodriguez-Cortes (principal investigator)Taking people
- Golisano Children's Hospital of Southwest FloridaFort Myers, United StatesContact: Emad K. Salman (principal investigator)Taking people
- Cook Children's Medical CenterFort Worth, United StatesContact: Kenneth M. Heym (principal investigator)Taking people
- UF Health Cancer Institute - GainesvilleGainesville, United StatesContact: Brian Stover (principal investigator)Taking people
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's HospitalGrand Rapids, United StatesContact: Kathleen Y. Butler (principal investigator)Taking people
- Saint Vincent Hospital Cancer Center Green BayGreen Bay, United StatesContact: Catherine A. Long (principal investigator)Taking people
- BI-LO Charities Children's Cancer CenterGreenville, United StatesContact: Aniket Saha (principal investigator)Taking people
- East Carolina UniversityGreenville, United StatesContact: Andrea R. Whitfield (principal investigator)Taking people
- Hackensack University Medical CenterHackensack, United StatesContact: Jing Chen (principal investigator)Taking people
- Connecticut Children's Medical CenterHartford, United StatesContact: Michael S. Isakoff (principal investigator)Taking people
- Penn State Children's HospitalHershey, United StatesContact: Lisa M. McGregor (principal investigator)Taking people
- Memorial Regional Hospital/Joe DiMaggio Children's HospitalHollywood, United StatesContact: Iftikhar Hanif (principal investigator)Taking people
- Kapiolani Medical Center for Women and ChildrenHonolulu, United StatesContact: Wade T. Kyono (principal investigator)Taking people
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer CenterHouston, United StatesContact: Eric S. Schafer (principal investigator)Taking people
- UT MD Anderson Cancer CenterHouston, United StatesContact: Najat C. Daw (principal investigator)Taking people
- Edwards Comprehensive Cancer CenterHuntington, United StatesNo longer taking part
- Ascension Saint Vincent Indianapolis HospitalIndianapolis, United StatesContact: Bassem I. Razzouk (principal investigator)Taking people
- Riley Hospital for ChildrenIndianapolis, United StatesContact: Sandeep Batra (principal investigator)Taking people
- University of Iowa/Holden Comprehensive Cancer CenterIowa City, United StatesContact: Andrew P. Groves (principal investigator)Taking people
- University of Mississippi Medical CenterJackson, United StatesContact: Amanda Strobel (principal investigator)Taking people
- Nemours Children's Clinic-JacksonvilleJacksonville, United StatesContact: Sridhi Patel (principal investigator)Taking people
- Bronson Methodist HospitalKalamazoo, United StatesContact: Kathleen Y. Butler (principal investigator)Taking people
- Children's Mercy Hospitals and ClinicsKansas City, United StatesContact: Keith J. August (principal investigator)Taking people
- East Tennessee Childrens HospitalKnoxville, United StatesContact: Susan E. Spiller (principal investigator)Taking people
- Alliance for Childhood Diseases/Cure 4 the Kids FoundationLas Vegas, United StatesContact: Alan K. Ikeda (principal investigator)Taking people
- Summerlin Hospital Medical CenterLas Vegas, United StatesContact: Alan K. Ikeda (principal investigator)Taking people
- Sunrise Hospital and Medical CenterLas Vegas, United StatesNo longer taking part
- University Medical Center of Southern NevadaLas Vegas, United StatesNo longer taking part
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer CenterLebanon, United StatesContact: Angela Ricci (principal investigator)Taking people
- University of Kentucky/Markey Cancer CenterLexington, United StatesContact: James T. Badgett (principal investigator)Taking people
- Arkansas Children's HospitalLittle Rock, United StatesContact: Michael W. Bishop (principal investigator)Taking people
- Loma Linda University Medical CenterLoma Linda, United StatesContact: Albert Kheradpour (principal investigator)Taking people
- Miller Children's and Women's Hospital Long BeachLong Beach, United StatesContact: Jacqueline N. Casillas (principal investigator)Taking people
- Cedars-Sinai Medical CenterLos Angeles, United StatesContact: Nicole M. Baca (principal investigator)Taking people
- Children's Hospital Los AngelesLos Angeles, United StatesContact: Jamie L. Stokke (principal investigator)Taking people
- Mattel Children's Hospital UCLALos Angeles, United StatesNo longer taking part
- Norton Children's HospitalLouisville, United StatesContact: Michael J. Ferguson (principal investigator)Taking people
- Palms West Radiation TherapyLoxahatchee Groves, United StatesNo longer taking part
- Covenant Children's HospitalLubbock, United StatesContact: Kishor M. Bhende (principal investigator)Taking people
- UMC Cancer Center / UMC Health SystemLubbock, United StatesContact: Erin K. Barr (principal investigator)Taking people
- Atrium Health NavicentMacon, United StatesContact: Sushmita Nair (principal investigator)Taking people
- Valley Children's HospitalMadera, United StatesContact: Ruetima Titapiwatanakun (principal investigator)Taking people
- University of Wisconsin Carbone Cancer Center - University HospitalMadison, United StatesContact: Cathy A. Lee-Miller (principal investigator)Taking people
- Marshfield Medical Center-MarshfieldMarshfield, United StatesContact: Michelle A. Manalang (principal investigator)Taking people
- Loyola University Medical CenterMaywood, United StatesContact: Eugene Suh (principal investigator)Taking people
- Vannie Cook Children's ClinicMcAllen, United StatesContact: Juan C. Bernini (principal investigator)Taking people
- Banner Children's at DesertMesa, United StatesContact: Joseph C. Torkildson (principal investigator)Taking people
- Nicklaus Children's HospitalMiami, United StatesContact: Maggie E. Fader (principal investigator)Taking people
- University of Miami Miller School of Medicine-Sylvester Cancer CenterMiami, United StatesContact: Julio C. Barredo (principal investigator)Taking people
- Miami Cancer InstituteMiami, United StatesNo longer taking part
- Children's Hospital of WisconsinMilwaukee, United StatesContact: Michael J. Burke (principal investigator)Taking people
- NYU Langone Hospital - Long IslandMineola, United StatesContact: Chana L. Glasser (principal investigator)Taking people
- Children's Hospitals and Clinics of Minnesota - MinneapolisMinneapolis, United StatesContact: Michael K. Richards (principal investigator)Taking people
- University of Minnesota/Masonic Cancer CenterMinneapolis, United StatesContact: Peter M. Gordon (principal investigator)Taking people
- USA Health Strada Patient Care CenterMobile, United StatesContact: Hamayun Imran (principal investigator)Taking people
- West Virginia University HealthcareMorgantown, United StatesNo longer taking part
- Morristown Medical CenterMorristown, United StatesContact: Kathryn L. Laurie (principal investigator)Taking people
- The Children's Hospital at TriStar CentennialNashville, United StatesContact: Clinton M. Carroll (principal investigator)Taking people
- Vanderbilt University/Ingram Cancer CenterNashville, United StatesContact: Brianna N. Smith (principal investigator)Taking people
- Jersey Shore Medical CenterNeptune City, United StatesContact: Jing Chen (principal investigator)Taking people
- Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University HospitalNew Brunswick, United StatesContact: Marissa Botwinick (principal investigator)Taking people
- Saint Peter's University HospitalNew Brunswick, United StatesContact: Nibal A. Zaghloul (principal investigator)Taking people
- Yale UniversityNew Haven, United StatesContact: Farzana Pashankar (principal investigator)Taking people
- The Steven and Alexandra Cohen Children's Medical Center of New YorkNew Hyde Park, United StatesContact: Arlene S. Redner (principal investigator)Taking people
- Children's Hospital New OrleansNew Orleans, United StatesContact: Maria C. Velez-Yanguas (principal investigator)Taking people
- Ochsner Medical Center JeffersonNew Orleans, United StatesContact: Craig Lotterman (principal investigator)Taking people
- Laura and Isaac Perlmutter Cancer Center at NYU LangoneNew York, United StatesContact: Elizabeth A. Raetz (principal investigator)Taking people
- Memorial Sloan-Kettering Cancer CenterNew York, United StatesContact: Kavitha Ramaswamy (principal investigator)Taking people
- Mount Sinai HospitalNew York, United StatesContact: Pamela R. Merola (principal investigator)Taking people
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer CenterNew York, United StatesContact: Nobuko Hijiya (principal investigator)Taking people
- NYP/Weill Cornell Medical CenterNew York, United StatesContact: Jaclyn Rosenzweig (principal investigator)Taking people
- Newark Beth Israel Medical CenterNewark, United StatesContact: Teena Bhatla (principal investigator)Taking people
- Children's Hospital of The King's DaughtersNorfolk, United StatesContact: Melissa S. Mark (principal investigator)Taking people
- Advocate Children's Hospital-Oak LawnOak Lawn, United StatesContact: Rebecca E. McFall (principal investigator)Taking people
- Kaiser Permanente-OaklandOakland, United StatesContact: Aarati V. Rao (principal investigator)Taking people
- UCSF Benioff Children's Hospital OaklandOakland, United StatesContact: Karen R. Rabin (principal investigator)Taking people
- University of Oklahoma Health Sciences CenterOklahoma City, United StatesContact: Rene Y. McNall-Knapp (principal investigator)Taking people
- Children's Hospital and Medical Center of OmahaOmaha, United StatesContact: Jill C. Beck (principal investigator)Taking people
- University of Nebraska Medical CenterOmaha, United StatesContact: Jill C. Beck (principal investigator)Taking people
- Children's Hospital of Orange CountyOrange, United StatesContact: Elyssa M. Rubin (principal investigator)Taking people
- AdventHealth OrlandoOrlando, United StatesContact: Fouad M. Hajjar (principal investigator)Taking people
- Arnold Palmer Hospital for ChildrenOrlando, United StatesContact: Zhongbo Hu (principal investigator)Taking people
- Nemours Children's HospitalOrlando, United StatesContact: Sridhi Patel (principal investigator)Taking people
- Lucile Packard Children's Hospital Stanford UniversityPalo Alto, United StatesContact: Jay Michael S. Balagtas (principal investigator)Taking people
- Advocate Children's Hospital-Park RidgePark Ridge, United StatesContact: Rebecca E. McFall (principal investigator)Taking people
- Saint Joseph's Regional Medical CenterPaterson, United StatesContact: Alissa Kahn (principal investigator)Taking people
- Nemours Children's Clinic - PensacolaPensacola, United StatesContact: Jeffrey H. Schwartz (principal investigator)Taking people
- Sacred Heart HospitalPensacola, United StatesNo longer taking part
- OSF Children's Hospital of IllinoisPeoria, United StatesContact: Prerna Kumar (principal investigator)Taking people
- Children's Hospital of PhiladelphiaPhiladelphia, United StatesContact: Susan R. Rheingold (principal investigator)Taking people
- Saint Christopher's Hospital for ChildrenPhiladelphia, United StatesContact: Gregory E. Halligan (principal investigator)Taking people
- Phoenix Childrens HospitalPhoenix, United StatesContact: Dana B. Salzberg (principal investigator)Taking people
- Children's Hospital of Pittsburgh of UPMCPittsburgh, United StatesContact: Lisa Maurer (principal investigator)Taking people
- Legacy Emanuel Children's HospitalPortland, United StatesContact: Jason M. Glover (principal investigator)Taking people
- Oregon Health and Science UniversityPortland, United StatesContact: Bill H. Chang (principal investigator)Taking people
- Naval Medical Center - PortsmouthPortsmouth, United StatesContact: Karin Brockman (principal investigator)Taking people
- Rhode Island HospitalProvidence, United StatesContact: Bradley DeNardo (principal investigator)Taking people
- Renown Regional Medical CenterReno, United StatesContact: Seema L. Rao (principal investigator)Taking people
- VCU Massey Comprehensive Cancer CenterRichmond, United StatesContact: Jordyn R. Griffin (principal investigator)Taking people
- Carilion Children'sRoanoke, United StatesContact: Erwood G. Edwards (principal investigator)Taking people
- Mayo Clinic in RochesterRochester, United StatesContact: Madeleine O'Keefe (principal investigator)Taking people
- University of RochesterRochester, United StatesContact: Rafi R. Kazi (principal investigator)Taking people
- Corewell Health Children'sRoyal Oak, United StatesContact: Marie V. Nelson (principal investigator)Taking people
- Sutter Medical Center SacramentoSacramento, United StatesContact: Sandra Baril (principal investigator)Taking people
- University of California Davis Comprehensive Cancer CenterSacramento, United StatesContact: Marcio H. Malogolowkin (principal investigator)Taking people
- Primary Children's HospitalSalt Lake City, United StatesContact: Luke D. Maese (principal investigator)Taking people
- Children's Hospital of San AntonioSan Antonio, United StatesContact: Julie Voeller (principal investigator)Taking people
- Methodist Children's Hospital of South TexasSan Antonio, United StatesContact: Jose M. Esquilin (principal investigator)Taking people
- University of Texas Health Science Center at San AntonioSan Antonio, United StatesContact: Anne-Marie R. Langevin (principal investigator)Taking people
- Naval Medical Center -San DiegoSan Diego, United StatesContact: Yoko T. Udaka (principal investigator)Taking people
- Rady Children's Hospital - San DiegoSan Diego, United StatesContact: William D. Roberts (principal investigator)Taking people
- UCSF Medical Center-Mission BaySan Francisco, United StatesContact: Karen R. Rabin (principal investigator)Taking people
- Santa Barbara Cottage HospitalSanta Barbara, United StatesContact: Shivani Upadhyay (principal investigator)Taking people
- Memorial Health University Medical CenterSavannah, United StatesContact: Andrew L. Pendleton (principal investigator)Taking people
- Maine Children's Cancer ProgramScarborough, United StatesContact: Eric C. Larsen (principal investigator)Taking people
- Seattle Children's HospitalSeattle, United StatesContact: Sarah E. Leary (principal investigator)Taking people
- Sanford USD Medical Center - Sioux FallsSioux Falls, United StatesContact: Jordan Fritch-Hanson (principal investigator)Taking people
- Providence Sacred Heart Medical Center and Children's HospitalSpokane, United StatesContact: Judy L. Felgenhauer (principal investigator)Taking people
- Baystate Medical CenterSpringfield, United StatesContact: Joanna G. Luty (principal investigator)Taking people
- Southern Illinois University School of MedicineSpringfield, United StatesNo longer taking part
- Cardinal Glennon Children's Medical CenterSt Louis, United StatesContact: William S. Ferguson (principal investigator)Taking people
- Mercy Hospital Saint LouisSt Louis, United StatesContact: Robin D. Hanson (principal investigator)Taking people
- Washington University School of MedicineSt Louis, United StatesContact: Kristin Zorn (principal investigator)Taking people
- Johns Hopkins All Children's HospitalSt. Petersburg, United StatesContact: Jennifer B. Dean (principal investigator)Taking people
- Stony Brook University Medical CenterStony Brook, United StatesContact: Laura E. Hogan (principal investigator)Taking people
- State University of New York Upstate Medical UniversitySyracuse, United StatesContact: Melanie A. Comito (principal investigator)Taking people
- Mary Bridge Children's Hospital and Health CenterTacoma, United StatesContact: Robert G. Irwin (principal investigator)Taking people
- Madigan Army Medical CenterTacoma, United StatesNo longer taking part
- Saint Joseph's Hospital/Children's Hospital-TampaTampa, United StatesContact: Don E. Eslin (principal investigator)Taking people
- Tampa General HospitalTampa, United StatesContact: Andrew J. Galligan (principal investigator)Taking people
- Scott and White Memorial HospitalTemple, United StatesContact: Nicholas W. McGregor (principal investigator)Taking people
- Montefiore Medical Center - Moses CampusThe Bronx, United StatesContact: Alice Lee (principal investigator)Taking people
- ProMedica Toledo Hospital/Russell J Ebeid Children's HospitalToledo, United StatesContact: Jamie L. Dargart (principal investigator)Taking people
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical CenterTorrance, United StatesNo longer taking part
- Banner University Medical Center - TucsonTucson, United StatesContact: Holly E. Pariury (principal investigator)Taking people
- Saint Francis Children's HospitalTulsa, United StatesContact: Jill A. Salo (principal investigator)Taking people
- New York Medical CollegeValhalla, United StatesContact: Andrew J. Bellantoni (principal investigator)Taking people
- Children's National Medical CenterWashington D.C., United StatesContact: Jeffrey S. Dome (principal investigator)Taking people
- MedStar Georgetown University HospitalWashington D.C., United StatesNo longer taking part
- Saint Mary's Medical CenterWest Palm Beach, United StatesContact: Matthew D. Ramirez (principal investigator)Taking people
- Wesley Medical CenterWichita, United StatesContact: Nathan S. Hall (principal investigator)Taking people
- Alfred I duPont Hospital for ChildrenWilmington, United StatesContact: Sridhi Patel (principal investigator)Taking people
- Northwestern Medicine Central DuPage HospitalWinfield, United StatesContact: Sara Zarnegar-Lumley (principal investigator)Taking people
- Wake Forest University Health SciencesWinston-Salem, United StatesContact: Sarah Supples (principal investigator)Taking people
- UMass Memorial Medical Center - University CampusWorcester, United StatesContact: Stefanie R. Lowas (principal investigator)Taking people
About the trial
What the trial wants to find out
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy and immunotherapy (chemo-immunotherapy) for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. Inotuzumab ozogamicin is a monoclonal antibody, which is a type of protein that can bind to certain targets on the surface of cells. Inotuzumab ozogamicin is a monoclonal antibody that is linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells by binding to the CD22 protein on the surface of the cancer cell and delivering calicheamicin inside the cells to kill them. Other drugs used in the chemotherapy regimen, such as cyclophosphamide, cytarabine, dexamethasone, doxorubicin, daunorubicin, methotrexate, leucovorin, mercaptopurine, prednisone, thioguanine, vincristine, and pegaspargase or calaspargase pegol work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Blinatumomab is a specialized type of monoclonal antibody known as a bispecific T-cell engager (BiTE). It works by simultaneously binding to CD19 on cancer cells and CD3 on normal immune cells, bringing them together to destroy leukemia cells. Blinatumomab is a standard part of chemo-immunotherapy treatment for B-ALL. This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy without inotuzumab ozogamicin or blinatumomab.
Read full original descriptionShow less
The overall goal of this study is to understand if adding inotuzumab ozogamicin to standard of care chemo-immunotherapy maintains or improves outcomes in High Risk B-cell Acute Lymphoblastic Leukemia (HR B-ALL). The first part of the study includes the first phase of therapy: Induction. This part will collect information on the leukemia, as well as the effects of the initial treatment, to classify patients into post-induction treatment groups. On the second part of this study, patients with HR B-ALL will receive the remainder of the chemotherapy cycles (consolidation, blinatumomab block 1, interim maintenance 1, blinatumomab block 2, delayed intensification, interim maintenance 2, maintenance), with some patients randomized to receive inotuzumab. The patients that receive inotuzumab will not receive part of consolidation or part of delayed intensification. Other aims of this study include evaluating 1) side effects of treatment using patient-reported outcomes and health-related quality of life, 2) the best ways to help patients adhere to oral chemotherapy regimens, 3) the relationship between levels of inotuzumab ozogamicin in the blood and side effects, 4) the impact of chemo-immunotherapy on the immune system and risk of infection, and 5) the impact of social determinants of health on outcomes. Finally, this study will be the first to track the outcomes of subjects with disseminated B-cell Lymphoblastic Leukemia (B-LLy) or Mixed Phenotype Acute Leukemia (MPAL) when treated with B-ALL chemotherapy.
The 4 groups in the trial
- Arm D (CD 22 positive HR B-ALL)Existing treatment, for comparison
See detailed description for Arm D.
Treatment: Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration, Bone Marrow Biopsy, Calaspargase Pegol, Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin Hydrochloride, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Prednisolone, Prednisone, Questionnaire Administration, Radiation Therapy, Thioguanine, and Vincristine Sulfate
- Arm E (CD22 positive HR B-ALL)Treatment being tested
See detailed description for Arm E.
Treatment: Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration, Bone Marrow Biopsy, Calaspargase Pegol, Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin Hydrochloride, Inotuzumab Ozogamicin, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Prednisolone, Prednisone, Questionnaire Administration, Radiation Therapy, and Vincristine Sulfate
- Arm I (MPAL)Treatment being tested
See Detailed Description for Arm I.
Treatment: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Calaspargase Pegol, Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Prednisolone, Prednisone, Questionnaire Administration, Radiation Therapy, Thioguanine, and Vincristine Sulfate
- Arm II (B-LLy)Treatment being tested
See Detailed Description for Arm II.
Treatment: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Bone Scan, Calaspargase Pegol, Computed Tomography, Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin Hydrochloride, Leucovorin Calcium, Magnetic Resonance Imaging, Mercaptopurine, Methotrexate, Pegaspargase, Positron Emission Tomography, Prednisolone, Prednisone, and Questionnaire Administration
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
- Plain-language title
- Tests inotuzumab ozogamicin added to chemo-immunotherapy in high-risk childhood B-cell leukemiaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Publications
- Immunotherapy in B-Cell Acute Lymphoblastic Leukemia.Journal of the National Comprehensive Cancer Network : JNCCN, 2025
- Record updated
- 25 August 2026